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Summary
15 SM/J mouse hybridoma antibodies that show antithymocyte autoantibody (ATA) activity
by immunofluorescence staining were studied. Half of these antibodies react with determinants
whose expression is associated with Thy-1, as shown by blocking experiments with antiThy-1
and loss of reactivity with Thy-1 - mutant cell lines . The Thy-1 dependence of three of these
ATA is further confirmed by their reexpression on a Thy-1 gene transfectant . However, the remaining
antibodies exhibited binding that showed little or no dependence on Thy-1 . Furthermore, we
find that most ATA derives from the Ly-1B subpopulation, as demonstrated by lipopolisaccharide-
induced ATA secretion in vitro and by comparison ofATA hybridoma frequencies. V region
gene sequence data of 14 monoclonal ATA from Ly-1 B cell-derived hybridomas reveal the utiliza-
tion of nine V genes belonging to four different VH families (J558, 3609, Q52, and Vgam3.8) .
While we find that two of these hybridomas arose from a clonal expansion, we also find four
examples of a 3609 family V gene utilized in clonally independent lines showing similar spec-
ificity. Yet another example of identical V gene usage by clonally unrelated cells is found in
two J558 ATA of a distinct fine specificity . These data suggest that the enrichment of ATA B
cells in the Ly-1 B subset is primarily due to repeated independent recruitment of B cells by
antigen resulting in the expression of a restricted set of VH genes.
T
he existence of spontaneously occurring autoantibodies
has been recognized formany years (1-7) . Since the serum
levels of these antibodies do not show etiologic relevance to
disease (8), the pathologic significance of such "natural" auto-
antibodies is not clear. One of these natural autoantibodies,
antibody to a cryptic determinant on erythrocytes (anti-bro-
melain-treated mouse RBC [anti-BrMRBC]'), is largely
contributed by a unique B cell subset, Ly-1 B (9, 10) . Ly-1
B comprises a minor (1-2%) subset in the normal secondary
lymphoid organ (spleen) or PBL, whereas it is uniquely en-
riched in mouse peritoneal cavity (PerC) (11-13). Ly-1 (CD5)
expression has also been found on late-developing IgM+ B
lymphomas (14) . From our previous data with cell transfer ex-
periments, we suggest that Ly-1 B constitutes a distinctB cell
lineage ; most Ly-1 B cells present in adult mice are the progeny
of cells generated from an earlyB cell source (fetal liver) (15),
are maintained by self-renewal, and poses the potential for
disregulated growth later in life (13, 14, 16-19) .
'Abbreviations used in this paper. APC, allophycocyanin ; ATA, anti-
thymocyte autoantibody ; BrMRBC, bromelain-treated mouse RBC ;
PerC, peritoneal cavity .
Although thebiological role ofLy-1 B in theimmune system
is not clearly understood, this subset appears to be phylogen-
ically conserved since it is found in both mice and humans
(13, 20) . One fundamental question relating to the biolog-
ical function of Ly-1 B is the extent of its contribution to
autoantibody secretion and the mechanism to allow such ex-
pression . Although enrichment of autoantibody specificities
in this B cell subset has been suggested previously (11, 13),
explicit determination of the antibody specificities (and V
genes) characterizing Ly-1 B would provide help in answering
these questions . In murine Ly-1 B, the anti-BrMRBC
specificity encoded by V11 (together with V,,9) provided
the first example demonstrating such bias (9, 10, 21) . These
V genes have also been found recurrently (in an unmutated
form) in the B lymphomas mentioned above (19) .
We report here studies on the cellular origin, specificity,
and primary structure of a group of natural antithymocyte
autoantibodies (ATA) . ATA secretion occurs spontaneously
in normal animals, and these antibodies bind to intact thymo-
cytes (3, 4, 7, 8) . Although high levels of ATA have been
found in animals with autoimmune disease (e.g., NZB mice)
(4), they have also been detected at high levels in some strains
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Volume 172 September 1990 869-878of mice without apparent disorders (SM/J mice) (8). That
Ly-1 B might be the source of ATA was foreshadowed by
the fact that both NZB and SM/J mice have elevated levels
of Ly-1 B cells (10, 11, 13, 22) and increased frequencies of
anti-BrMRBC and ATA in their sera (4, 5, 8) . Furthermore,
as we previously reported, Ly-1 B in NZB mice are largely
responsible for the spontaneous secretion of IgM in vitro,
including ATA (9). However, whether this was due to the
unique predisposition of NZB Ly-1 B to secrete Ig spontane-
ously in vitro, or instead to a higher frequency of ATAspecific
B cellsin the Ly-1 B population, remained to be determined.
We now show that ATA-specific B cells are enriched among
Ly-1 B cells. To attempt to understand the mechanism resulting
in such a bias of specificity in Ly-1 B, we examined SM/J
Ly-1 B-derived antithymocyte hybridomas, defining their fine
antigen specificity and associated V gene usage. Earlier
work had suggested that the major antigens in ATA show
a common tissue distribution in most cases (8), probably in-
cluding determinant(s) on the Thy-1 molecule (4, 23-26).
However, heterogeneity in ATA determinants either related
or unrelated to Thy-1 has also been reported (4, 8, 27-30).
As we report here, natural ATA are composed of antibodies
specific for diverse determinants and encoded by various V
genes, with many of these antibodies recognizing antigens
(probably of carbohydrate nature) present on the Thy-1 gly-
coprotein. Furthermore, we found that similar specificities
recur between clonally unrelated ATA hybridomas, which ex-
hibit repeated usage of nearly identical VH genes. The im-
plications of this finding are discussed.
Materials and Methods
Animals.
￿
SM/J mice were purchased from The Jackson Labo-
ratory (Bar Harbor, ME). BALB/cAnN, AL/N and AKR/J mice,
and F344N rats were bred and maintained in the Institute for Cancer
Research animal facility. 2-4-mo-old female animals were used in
all experiments.
Immunofluorescence Staining and Sorting.
￿
Preparation ofcells, re-
agents for immunofluorescence staining, cell sorting using FACS
(FACStar plus; Becton Dickinson Immunocytometry Systems,
Mountain View, CA), and data analysis were all described previ-
ously (10, 31).
Induction ofATA Secretion In Vitro.
￿
Spleen cells from SM/J and
BALB/c mice and cells from the BALB/c PerC were stained with
fluorescein-anti-IgM(331.12) and allophycocyanin (APC)-anti-Ly-1
(53-7). 2-4-mo-old SM/J mice and BALB/c mice consistently show
4-7% and 1-2% Ly-1 B (Ly-1*IgM+) cells in spleen, respectively
(10,11,13) . Ly-1 B cells represent 10-30% of total cells in BALB/c
PerC (13). Ly-1 -B cells are identified as Ly-1 -IgM* cells in spleen.
Sorting of spleen cells lacking Ly-1 B (Ly-1 B depleted) or Ly-1 -B
(Ly-1- B depleted) was carried out by using the FACS sort gates
set to cancel the selected population. All cell cultures were initi-
ated at 106 cells/ml in RPMI 1640 + 10% FCS + 5 p,M 2-ME
with or without LPS (10 ttg/ml).
Production, Screening, and Cloning ofATA Hybridomas.
￿
ATA hy-
bridoma clones were produced and selected at the same time as
the anti-BrMRBC hybridomas reported previously (10). Briefly,
after staining of spleen cells pooled from five SM/J mice, Ly-1 B
and Ly-1- (IgD++) B cells were isolated by sorting, cultured for
2 d in the presence ofLPS, and then hybridizedwith aHATsensitive
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MPC11 myeloma cell line (,y2b,K). Six 96-well plates (estimated
threeto four clones/well) (10) from the Ly-1 B hybridization were
all positive for IgM secretion, and their supernatants were screened
for ATA activity by immunofluorescence staining on SM/J mouse
thymocytes, as revealed by APC-anti-IgM (331.12). Simultaneously,
thesesupernatants were tested for anti-BrMRBC, anti-mouse RBC
(MRBC), anti-splenic B cell, and anti-bone marrow cell activities
by staining and for anti-ssDNAand anti-mouse IgG activities by
an ELISA. Most ATApositive wells did not show crossreactivity
in these assays, with the exception of one well (showing binding
to ssDNA, cloned as 1-6D7). Ly-1 - B cell hybridomas were
screened only for ATA activity. ATA-positive wellswere cloned by
cell sorter immediately after the screening.
Analysis ofMonoclonalATA Reactivityto Various Cell Types.
￿
Hy-
bridomas were maintained in Opti-MEM (Gibco Laboratories,
Grand Island, NY) + 4% FCS + 2-ME. Ascites was produced
in CB.17 scid mice, and 25 ul of 1/100 diluted ascites for 5 x 105
cells was used for immunofluorescence staining (revealed by APC-
anti-IgM; 331.12). For thymocyte, splenic T cell and bone marrow
staining, BALB/c mice (which show comparable staining with SM/J
mice) were normally used, except for MG10 (negative with
BALB/c), where AKR mice were used. For splenic non-T cell-
staining, AL/N mice (negative with 331.12) were used to avoid
B cell staining by second-step anti-IgM antibody. AL/N thymo-
cytes were stained by all ATA used here.
AntiThy-1 Blocking.
￿
To examine the blocking of ATA staining
by antiThy-1 antibody, 10 Wg of rat anti Thy-1.2 (30-1112) or rat
antiThy-1.1 (T11D7e2; provided by Dr. M. Dailey, University of
Iowa) antibody was used simultaneously with limiting dilutions
(1/100-1/3,000) ofATA for BALB/c and AKR thymocyte staining,
respectively. Anti-CD45 (30F11) and anti-CD5 (53-7) antibodies
were used as negative controls.
Sodium mperiodate Treatment.
￿
Thymocyteswere fixedwith 3%
(wt/vol) paraformaldehyde in PBS, washed, and treated with or
without 0.08 M sodium m-periodate in 0.05 M sodium acetate
buffer, pH 5 .5, at 37°C for 2 h, as described elsewhere (32, 33).
T Lymphoma Cell Linesand TheirMutants.
￿
BW5147(Thy-1- a)
and BW5147(Thy-1 -e) are Thy-1 - mutant cell lines derived from
BW5147(Thy-1+) wild type (34, 35). Both class A and E mutants
are defective in the anchoring of membrane Thy-1 glycoproteins
via the phosphatidylinositol-containing glycolipid anchor ofThy-
1 (36), and the class E mutant has a mutation in the gene coding
for GDP-mannose:dolichol-P-mannosyltransferase, which presum-
ably affects the biosynthesis of glycolipid tails in addition to the
biosynthesis ofWinked high-mannose oligosaccharides (36, 37).
The AKR1(Thy-1 -d) cell line is a class D mutant from AKR1
(Thy-1+) wild type. This mutant has a deletion of the 5' portion
of the Thy-1 gene including the first two alternatively used exons
and promoters and a portion of the second intron (38). TFX351
is a Thy-1.1+ transfectant of AKR1(Thy-1 -d). An 8.1-kb EcoRI
genomic fragment containing the Thy-1.1 gene (39) was ligated
into the vector pSV2gpt (40) in an inverse orientation to the SV40
enhancer. This construct was introduced into AKR1 (Thy-1 -d)
by electroporation.
Sequence Determinations ofIgH Variable Regions ofRNA.
￿
Poly-
(A)+ mRNA was isolated from hybridomas and sequenced by h
primer extension, as described previously(10), in most cases. The
3609 sequences showed several strong stopsin sequencing by primer
extension, so an alternate method using PCR was used for these
clones. A first-strand cDNA was synthesized from mRNA with
reverse transcriptase, then oligos complementary to the 5' region
of FW1(5'-TTACTCTAAAAGAGTCTGGCCCTGGG-3') of the
3609 gene and to the 5' region of the CIA sequence (5'-GGCTCTLy-1 BCellsAreResponsibleforATASecretion.
￿
Spleen cells
from mice of the nonautoimmune SM/J strain, unlike most
mouse strains, secrete IgM ATA detectable by immunofluores-
cence staining after stimulation with LPS in culture (Fig. 1
a). We found that this ATA secretion from SM/J spleen was
completely eliminated after depletion of Ly-1 B cells (com-
prising 5% of spleen cells; reference 10) without a significant
decrease in the total IgM produced (Fig. 1 a). Depletion of
Ly-1 -B cells (the majority of B cells in spleen) did not affect
ATA secretion (Fig. 1 a) whereas, as expected, total IgM and
B cell proliferation (data not shown) were greatly reduced.
10 100
Ly-1B depleted
--«-Ly-i~B depleted
"--unseparated
- (-)
CGCAGGAGACGAGGG-3') were added, andfinallythemixture
was amplified in a standard PCR reaction. After gel purification,
theDNAwasthen sequencedin adouble-stranded sequencingpro-
cedure (41) using the original PCR primers. Mouse p, and other
oligonucleotide primers used for sequencing and as PCR primers
were synthesized usingphosphotriester chemistry by an oligonu-
cleotide synthesizer (Applied Biosystems, Inc., Foster City, CA)
without further purification. Sequences were analyzed with the
Wisconsin Sequence Package running on a VAX computer (Dig-
ital Equipment Corp., Burlington, MA) as describedpreviously (10).
Results
Culture Supernatant from:
SM/J Spleen cells
a I
￿
b
SM/J Splenic B cells
￿
BALB/c B cells
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BALB/c B cells
10 loo
Ly-1 B (PerC)
Ly-1B (Spleen)
c
Figure 1.
￿
Ly-1 B cells in SM/J and BALB/c mice
secrete ATA after stimulation by LPS. The histogram
of the immunofluorescence staining of thymocytes by
the culture supernatant is shown. BALB/c mouse
thymocytes (5 x 105 cells/20 Kl) were incubated
with 100 t41 of 3-d culture supernatant on ice for 15
min and washed, and then bound IgM was revealed
by APC-anti-IgM in a second step. No binding was
seen in supernatant of cultures without LPS (data not
shown) or from LPS cultures of SM/J Ly-1 B
(Ly-1+B)-depleted spleen cells (a). Total IgM levels
present in culture supernatant of unseparated, Ly-1
B-depleted, and Ly-1 -B-depleted SM/J spleen cells
were 1.4 Rg/ml, 1.0 tag/ml, and 0.4 iug/ml, respec-
tively (a). IgM levels of other cultures (using cell
sorter-purified B cell fractions; b and c) are given in
Fig. 2.
Thus, the presence ofLy-1 B is required for LPS-induced ATA
secretion from SM/J mouse spleen cells.
We found that Ly-1 B cells are exclusively responsible for
ATA secretion, not only in SM/J mice but also in BALB/c
mice. Purified Ly-1 B and Ly-1 -B cells from SM/J spleen,
or BALB/c peritoneal cavity Ly-1 B cells and Ly-1 -B cells
from BALB/c spleen were used for comparing levels of ATA
secretion in LPS culture. As Fig. 1, b and c show, both super-
natants from Ly-1 B cells contain ATA activity. The ATA
binding activity determined by immunofluorescence staining
intensity correlates with ATA levels in the secreted IgM, as
shown in Fig. 2. Although Ly-1 B cell cultures initially se-
crete more IgM than Ly-1 -B cell cultures, no antithymocyte
activity was ever detected in the supernatant from Ly-1 -
(conventional) B cells during 7 d of LPS culture, even after
comparable levels of IgM were attained (Fig. 2). The possi-
bility that ATA secretion from Ly-1 -B cells in the LPS cul-
ture system might be dependent on T cells (or some other
cell type) could be excluded since Ly-1 B-depletedSM/J spleen
cells, which include all non-B cells in spleen, did not show
ATA activity during the course of culture (similar to results
using purified B cell populations). Thus, these data strongly
suggest that a distinct B cell subset, Ly-1 B, is responsible
Figure 2.
￿
Thymocyte binding activity was only de-
tected in culture supernatant from Ly-1 B cell ir-
respective of secreted IgM levels or the kinetics. ATA
activity was measured in 3- and 7-d LPS culture su-
pernatants from (a) Ly-1 B and Ly-1 - B cells in
SM/J spleen cells or (b) from BALB/c PerC Ly-1 B
and Splenic Ly-1- B. Binding activity is expressed as
the mean fluorescence intensity of thymocyte staining.
IgM concentrations used for staining (on the abscissa)
are proportional to the secreted antibody levels; (a)
Ly-1 B d3 (4.0 tug/ml) and d7 (9.0 hg/ml), Ly-1 - B
d3 (3.6 /4g/ml) and d7 (5.6 Ftg/ml); (b) Ly-1 B d3
(20.5 Ecg/ml) and d7 (43.0 lug/ml), and Ly-1 - B d3
(1.0 Rg/ml) and d7 (18.0 tag/ml). Data of 1:10 (a)
and 1:3 (b) diluted supernatants from Ly-1 B cell cul-
tures were also included in plots. Saturation of ATA
binding was observed at >10 Ag/ml of IgM in the
Ly-1 B supernatant.for natural ATA secretion in most strains, and further, that
the increased population of Ly-1 B cells in SM/J mice is respon-
siblefor the characteristically high levels of serum ATA found
in this mouse strain.
The Specificity ofATA HybridomasAre Diverse.
￿
ATA from
Ly-1 B cellswas characterized further by establishing hybrid-
omas. Hybridomas made from Ly-1 B and conventional
Ly-1 - (IgD2+) B cells sorted from a pool of SM/J mouse
spleen were plated in limiting dilution to assess the frequency
of clone/well, as described previously (10). Results from the
initial screening of 576 IgM secreting wells from both Ly-1
B and Ly-1 - B cell fusions showed that the frequency of
clones with antithymocyte binding reactivity from Ly-1 B
was higher, 1% (23/1,728-2,304; three to four clones/well;
reference 10) compared with 0.1% (3/2,880; five clones/well)
from Ly-1 - B cells, consistent with results of the ATA secre-
tion assay described above. From these positive wells, we iso-
lated 17 antithymocyte Ly-1 B hybridoma clones and one
Ly-1 - B hybridoma clone. Two ATA Ly-1 B hybridoma
clones were obtained in a separate cell fusion experiment (10).
Table 1 lists the 15 monoclonal ATA (14 from Ly-1 B, 1 from
Ly-1 - B) that were characterized further.
After isolating hybridoma clones, several distinct ATA
binding profiles to different cell types emerged. As Table 1
Table 1.
￿
ATA Hybridomas Derivedfrom Ly-1 B Are T Lineage Cell Specific and Recognize Diverse Determinants
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CD4
shows, all monoclonal IgM ATA from Ly-1 B cells selected
by thymocyte binding activity showed specific binding to T
lineage cells (among hernatopoietic cells tested). However,
their specificities appear diverse, exhibiting differential reac-
tivity to thymocytes at various maturational stages (data not
shown), variable binding to peripheral T cells (CD4+
and/or CD8+), and different degrees of species crossreac-
tivity (mouse/rat). Most reactwith thymocytes from all strains
oflaboratory mice tested, including SM/J (data not shown).
However, several show a preferential (or exclusive) binding
to certain strains of mice (for example, BALB/c vs. AKR,
as shown in Table 1), although the genetic basis for this has
not been determined. In contrast to the T lineage specificity
shown by these ATA from Ly-1 B, the single ATA obtained
from Ly-1 - 11 cells (3-6A12) bound to both thymocytes and
other cell types from BALB/c (and SM/J), but did not react
with any cells from AKR mice. These data illustrate that
ATA hybridomas exhibit fine specificities whose reactivity is
dependent on the cell type, differentiation stage, mouse strain,
or species. The grouping of ATA by putative fine specificity
is based on these staining results using normalcellsand results
from experiments described below.
Halfofthe ATA HybridomasRecognize Determinants Largely
Dependent on Thy-1 Expression.
￿
The reactivity patterns de-
Spleen
CD8
￿
non-T
￿
BM
￿
Rat thymus
Hybridoma antibodies prefixed with 1, 2, and 3 are from the hybridization of Ly-1 B with MPC11, Ly-1 B with SP2/0, and Ly-1 -B with
MPCIL 1-6C10 and 1-3G11 were reported as SM6C10 and SM3G11, respectively, in our previous papers (31, 46). + + +, +
￿
and -
>60%, 20-60%, 1-20%, and <1% positive cells, respectively.
* Preferential binding to BALB/c thyrnocytes.
t 1-6D7 is positive for anti-ssDNA activity, whereas other ATA are negative.
S Preferential binding to AKR thymocytes.
Group Clone IgH,L Thymus
1 (1) 2-2G7 IA,X1 + + +
1-6C10 A,rc + + +
1-11110 1A,u + + +
1-1D9 JA,ic + +
1-4F2 /A,u + +
(2) 1-6B9 p,u + + *
1-4A2 JA,u + + *
(3) 1-6D7t iA,a + +
II (1) 1-4F5 W,rc +S
(2) 1-3A2 h,K +
III 2-1C10 A,a + +
IV 1-1G10 /A,ic +S
V 1-3G11 /A,u +
1-3115 14rc +
VI 3-6A12 p.,K +scribed above led us to consider the involvement of carbohy-
drate structures as the antigenic determinants, since carbo-
hydrate components ofcell surface molecules are often altered
during cell development or differentiation, and can be ex-
pressed in a strain- or species-specific manner (42, 43). Sup-
porting this prediction, the reactivity of 11 of these autoan-
tibodies was sensitive to prior treatment of target cells with
sodium metaperiodate, which preferentially oxidizes terminal
sialic acid groups (32) (Table 2).
Thy-1 is a major glycoprotein of the thymus, so the ability
ofanti Thy-1 antibody to blockATA binding was investigated
by immunofluorescence staining (Table 2 and Fig. 3). The
binding of the eight group I ATA antibodies was nearly com-
pletely blocked by prior or simultaneous incubation of thymo-
cytes with anti Thy-l antibody, while the binding of two ATA
antibodies (group II) was partially blocked. Blocking by anti-
Thy-1.1 or antiThy-1.2 antibodies was specific to the appro-
priate Thy-1 allele, and other antibodies (anti-CD45, anti-
CD5) that react with determinants present on the majority
of thymocytes did not block (data not shown). This result
suggests that the determinant detected by these antibodies
either resides on the Thy-1 glycoprotein or on a molecule
that is present in close proximity to the Thy-1 glycoprotein.
Stained with anti-Thyl.l.
t No staining after treatment without periodate.
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To more directly study the relationship of the determinants
defined by the ATA antibodies ofgroups I and II to the Thy-1
molecule, the staining of these antibodies on a panel of cell
lines was examined. BW5147 is a Thy-1+ lymphoma derived
from AKR/J (Thy-1.1) mice, while BW5147 (Thy-1 -a) and
BW5147 (Thy-1-e) are Thy-1 - mutants with defects in
genes affecting post-translational steps necessary for cell sur-
face expression of the Thy-1 glycoprotein (and other cell sur-
face molecules anchored in the cell membrane through a
glycophospholipid moiety) (34-37). AKRl is also a Thy-1+
lymphoma derived from AKR/J mice, while AKRl
(Thy-1 -d) is a Thy-1 - mutant that has undergone deletion
of a portion of the Thy-1 structural gene (38). TFX351 is
a Thy-l+ derivative of AKRl (Thy-1 -d) in which a normal
copy ofthe Thy-1.1 structural gene was introduced by trans-
fection.
The staining results of ATA on this panel of cell lines are
summarized in Table 2, and examples of FACS profiles ob-
tained are shown in Fig. 3. The three ATA of group I show
an absolute concordance with expression of the Thy-l glyco-
protein. Therefore, it seemshighly likely that these ATA recog-
nize one or more determinants present on the Thy-1 glyco-
protein. The rest of group I ATA stain neither the wild-type
Table 2. Hafof ATA Determinants Are Dependent on Thy-1 Expression and Many Are Carbohydrates
BW5147 AKRI
Group Clone Periodate sensitivity Anti-Thy-1 block Wild Thy-1-a Thy-1-e Wild Thy-1-d TFX351
a-Thy-1" I+++ - - +++ - +++
I (1) 2-2G7 Yes Yes
1-6C10 Yes Yes
1-11110 Yes Yes
1-1D9 Yes Yes
1-4F2 Yes Yes
(2) 1-6139 Yes Yes
1-4A2 Yes Yes
(3) 1-6D7 No Yes
II (1) 1-4F5 Yes Part
(2) 1-3A2 No Part
III 2-1C10 Yes No +++ + ++ +++ ++ +++
IV 1-1G10 No No
V 1-3Gi1 Yes No
1-31-15 . . Yes No
VI 3-6A12 -t No
+ + +, + + - , + , : staining intensity.Thyrnocyte BW5147 AKR1
anti-Thy-1
￿
Thy-1 loss
￿
Thy-1 loss
Group Clone
￿
Blocking
￿
Variants
￿
/Transfectant
I 2-2G7
75-
1-6C10 5o-
25-
75
II
￿
1-4F5 50
25
75
III 2-1C10 50
25
75
(-)
￿
none 50
25
1 10 100
- (-)
￿
- BW5147
￿
- AKR1
- anti-Thy-1
￿
- BW5147 (Thy-1- a)
￿
- AKR1 (Thy-Td)
- BW5147 (Thy-Te)
￿
-TFX351
Figure 3.
￿
FACS profiles of the monoclonal ATA staining on
BALB/c thymocytes (and blocking effect by antiThy-1), BW5147-
derived Thy-1 - mutant cell lines, and AKRl-derived Thy-1 - mutant
and Thy-1 * transfectant.
AKRI cell line nor transfectant TFX351. However, these an-
tibodies do show moderate to weak staining on the wild-
type BW5147 cell line but do not stain either BW5147 mutant.
Antibodies of group II show binding, although weakly
with a somewhat brighter tail in the FACS profile, to the
class D mutant derived from AKRL Therefore, it is unlikely
that the determinant recognized by this antibody resides solely
on the Thy-1 glycoprotein. As with the group I antibodies,
group II ATA stainthe wild-type BW5147 cell lines, but nei-
ther Thy-1 - mutant derived from this cell line.
Consistent with the failure of anti Thy-1 antibodies to block
ATA of groups III-VI, ATA of these groups either failed to
stain any cell line, whether Thy-1+ or not (groups IV-VI),
or stained all cells, whether wild-type or mutant (group III).
The determinants for group V antibodies (1-3G11 and 1-3H5)
are present at high levels on mature T cells where their ex-
pression is uncorrelated with Thy-1. Recent studies show that
group V antibodies (1-3G11 and 1-3H5) react with carbohy-
drate determinant present on a glycolipid (ganghoside), which
is probably the predominant source for this determinant (Greer,
J., T Koerner, R.R. Hardy, K. Hayakawa, and J. Kemp,
manuscript in preparation).
These results suggest that most determinants for ATA are
carbohydrate structures that can be expressed on glycopro-
teins, glycoplipids, or possibly on both (42). In summary,
these ATA determinants can be grouped based primarily on
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their relatedness to Thy-1 (sensitivity to antiThy-1 blocking,
and expression on T lymphoma wild and variant cell lines)
and on their distinctive distribution on normal cell types.
Further subdivision is possible with respect to sensitivity to
periodate treatment and preferential expression in certain
mouse strains. In cases where the difference of binding ac-
tivity by ATA to T lineage cells and cell lines could be con-
sidered due to antibody avidity, they are classed in the same
group; e.g., in group I-1, levels of staining intensity on the
thymus with 1-1139 and 1-4F2 are lower than the others.
Y  Gene Usage in ATA. The results described above
imply that the ATA antigenic determinants could be quite
diverse. Diversity of ATA determinants is also suggested by
variation in antibody combining sites, as determined by V
region gene sequencing of ATA hybridomas. We found that
the antibody combining sites of 14 Ly-1 B-derived ATA are
encoded by VH genes belonging to four V families 0558,
3609, Q52, Vgam3.8; Table 3). Notably, our data revealed
that fine specificities definable by our assays correlate with
usage of particular V genes, with the exception of 2-2G7
(Q52/A1), whose specificity was not clearly distinguishable
from that of another set ofantibodies with the 3609/K com-
bination. Three groups of ATA use nearly identical V
genes: group I-1 uses 3609, group I-2 uses a J558 member,
and group V uses a differentJ558 gene. Table 4 shows a sum-
mary of further V region sequence data. Two clones of Gr
I-2 with identical VDJ sequence are derived from a clonal
expansion since they have identical VDJ sequences. In addi-
tion, Southern blots using pJ11 probe (44) reveal the same
size Ig H chain rearranged bands, including the presumptive
nonproductive alleles (data not shown). However, Table 4
also demonstrates that the repetitive usage of identical V
gene found in ATA is not due to clonal proliferation alone.
The four group I-13609 hybridomas are unrelated, as deter-
mined by D and JN differences. WG11 and 1-3H5 (in group
V) use identical V and JR genes, but are unrelated as dis-
tinguished by their D genes. In conclusion, identical V
gene usage in ATA hybridomas is due both to clonal expan-
sion and to independent incidence.
Discussion
Numerous studies have demonstrated that carbohydrate
structures can serve as differentiation antigens and oncofetal
antigens (42, 43). It becomes increasingly apparent,that an-
tibodies to specific cell types or tumor cells often react with
carbohydrate determinants, and several reports of"natural an-
tibodies" reactive with carbohydrate structures are available
(42, 43). Since comparable carbohydrate structures can be ex-
pressed on several glycoproteins, glycolipids, or on both, anal-
ysis of such specificities often results in obscure data when
attempting to ascertain the precise molecular determinants.
Another difficultyin the characterization of the target mole-
cules of natural autoantibodies is due to the frequently ob-
served temperature dependence oftheir binding (better at low
temperature), suggesting low avidity. Our approach has been
to establish monoclonal ATA and examine their reactivity to
normal cell types or to chemically modified thymocytes, theirTable 3.
￿
Utilization of Diverse VH Genes in ATA Hybridomas
Derivedfrom Ly-1 B Cells
' Ambiguous assignment.
' a,b,c,d,e: identity of VH genes within the same VH family deter-
mined by V region sequence data. a-e are arbitrary designations.
crossblocking effect with antiThy-1, and their reactivity to
Thy-1 - mutants or Thy-1 gene transfectants. Such analysis
has allowed us to conclude that whiledeterminants on thymo-
cytes recognized by natural ATA are diverse, particular
specificities predominate, and further, that most of these
specificities probably involve carbohydrate structures.
We found that many ATA are specific to determinants as-
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sociated with the Thy-1 glycoprotein, which is a heavily
glycosylated molecule (30% [wt/vol]) (45) and one of the
major glycoproteins present on mouse thymocytes. This also
confirms previous data of Thy-l-dependent determinant(s)
for ATA that were induced during the production of anti-
Thy-1 polymorphic antibody after allogeneic thymocyte in-
jection (24, 26). However, while Thy-1 plays a major role,
our data also provides several examples of determinants un-
related to Thy-1, and also leaves open the possibility that even
the Thy-l-dependent determinants in the thymus might also
be expressed on different molecules in other organs or on
tumor cells. This may relate to the earlier finding that ATA
is detectable in the serum of athymic nude mice (7), and it
is interesting to speculate on the relation of some natural ATA
to natural anti-tumorcell activity found in sera (6). Neverthe-
less, our data suggests that natural autoantibodies specifically
recognize fine structures on cell surface molecules that can
be altered during differentiationand maturation. Our previous
studies of 600 and 3G11 expression on CD4+ T cell sub-
sets provide a clear case of such alteration (31, 46) .
Intriguingly, we found that although the ATA defined by
thymocyte binding activity show diverse specificities, the B
cellsthat produce such autoantibodies are not randomly dis-
tributed among B cell populations; that is, ATA B cells are
enriched in a minor B cell subset, Ly-1 B. Our data depend
on LPS responsiveness in vitro, and further work willbe neces-
sary to assess the frequency of ATAB cells in unmanipulated
cell populations. However, an elevated frequency of ATA B
cells in Ly-1 B can be expected since both Ly-1 B cell and
conventional B cell fusions generated after LPS culture showed
no obvious differences with regard to fusion frequency or
production of IgM-secreting wells. Therefore, our results for
ATA B cell frequency and ATA secretion lead us to suggest
that the ATA naturally found in serum derives solely from
Ly-1 B. An increased frequency of the Ly-1 B subset may ac-
Table 4. Identical VH Gene Usage in ATA Hybridomas Is Due Both to Clonal Expansionand to Independent Incidence
D region
Group Clone Vt, gene Size Amino acid residue Type JH
NT
1 (1) 1-6C10 3609' 18 REGGRS Q52 J2
1-1B10 3609' 18 RKGDYD Q52 J1
1-1139 3609' 27 RGLRYGTWG SP2-7 J1
1-4F2 3609' 21 RWNYYGL FL16-2 J4
(2) 1-6B9 J558' 9 EGS -' J3
1-4A2 J558' 9 EGS -' J3
V 1-3G11 J558° 12 EDWP SP2 J2
1-3115 J558° 24 LGWDVPEI Q52 J2
Group Clone V,, gene'
I (1) 2-2G7 Q52'
1-6C10 3609'
1-1B10 3609'
1-1139 3609'
1-4F2 3609'
(2) 1-6B9 J558'
1-4A2 J558'
(3) 1-6137 Vgam3.8
11 (1) 1-4F5 J558b
(2) 1-3A2 J558°
III 2-1C10 J558d
IV 1-1G10 Q52b
V 1-3G11 J558°
1-3115 J558°count for high levels of ATA in serum, as has been found
for NZB and SM/J mice.
The mechanism(s) that results in such a bias ofATAspecific
clones in Ly-1 B has not been elucidated. Perhaps key to this
question, we found that among various V genes encoding
ATA specificities, nearly identical V genes are used in
clonally unrelated hybridomas showing similar specificity. One
such example, 1-3G11 and 1-3H5, also appears to have iden-
tical L chains (sharing an identically size rearranged band with
the PECK probe by Southern analysis with several enzymes;
data not shown). Similar L chain analysis of ATA hybrid-
omas utilizing the 3609 V gene show different sized bands,
although their sequences need to be determined to definitely
answer the question of L chain usage. Nevertheless, the ob-
servation of similar binding specificity with identical V
gene usage by clonally unrelated cells suggests that ATAspecific
B cells were enriched among Ly-1 B cells primarily due to
their specificity, likely by an antigen-driven selection mecha-
nism. The origins of such antigens are not clear. However,
we presume natural ligands (environmental or auto-antigens)
are the most likely candidates for long-term constant selec-
tion of such B cells among Ly-1 B, and furthermore, prob-
ably lead in part to antibody secretion recognized as sponta-
neous natural ATA secretion in the serum. We found that
clonal proliferation of Ly-1 B cells, as reported elsewhere
(16-18), also contributes to the higher ATA frequency in Ly-
1 B. We speculate that a similar selection mechanism may
have been operating even in the event of clonal proliferation,
resulting in the increase of ATA B cells specifically, as has
been suggested in the generation of Ly-1 + B lymphomas
(19). Therefore, if we expanded our ATA,panel with more
Ly-1 B-derived hybridomas, we would likely find that all V
genes we have described in this paper would be observed
repeatedly.
Close examination of the D region sequence data (Table
4) reveals several unusual features in the ATA hybridomas:
the arginine (R)-rich sequences of Gr I-13609 V ATA, the
short D of Gr I-2, and the apparent D-D fusion of 1-3H5.
One possible explanation for the common arginine at the
start of the 3609-encoded D segments is that the first two
nucleotides may derive from the end of the V segment: in
every case the arginine is encoded by a codon that begins
with AG. Alternatively, the unique characteristics of argi-
nine may play a role in the binding site of Gr I-1 type ATA
antibodies. Unfortunately, the absence ofgermline sequence
data precludes any definitive conclusion regarding the origin
of this arginine. The short three amino acid residue D se-
quence in Gr I-2 is reminiscent ofthe three residue D always
found with V11-encoded anti-BrMRBC autoantibodies
(also derived from Ly-1 B), but numerous examples exist of
longer D segments in Ly-1 B-derived autoantibodies, so the
significance of such a short D remains equivocal. Finally, the
D segment in 1-3H5 appears to be the result of a D-D fu-
sion, a relatively uncommon event in normal rearrangement .
It is interesting to note that the most similar antibody, 1-3G11,
has a short D (different from 1-3H5) and that every residue
found in 1-3G11 is also found in 1-3H5, although arising
completely differently. Thus, we might speculate that these
four residues could play a role in the selection of ATA ac-
tivity of the type in Gr V
Our data show ATA to be the second autoantibody
specificity enriched in the Ly-1 B cell repertoire. We have pre-
viously shown another natural antibody, which to BrMRBC,
originates almost exclusively from Ly-1 B cells(9, 10) . Com-
pared with antigenic determinants for ATA, those on Br-
MRBC are much more restricted: they are recognized by anti-
BrMRBC autoantibodies that predominantly utilize either
a V11 gene together with a V,,9 gene or else a V12 gene
together with a V,,4 gene (10, 47). Our recent data by PCR
amplification ofDNA from purified B cell populations demon-
strates that Ly-1 B overutilize the VH11 gene, as compared
with other (conventional) B cells, due to a selection mecha-
nism rather than any restriction of particular V genes to this
subpopulation (21). Reminiscent of anti-BrMRBC antibodies,
the finding of repeated usage of the 3609 V gene in the
most common ATA specificity is of particular interest, con-
sidering its large contribution to the enrichment of ATA-
specific B cells in Ly-1 B, whereas members of the 3609 V
family have only infrequently been seen in conventional an-
tigen responses. However, our result also suggests that di-
verse V genes (from several frequently used V families) also
characterize the Ly-1 B repertoire established in adult mice.
We emphasized here the importance of antigen specificity
in contributing to positive selection in the Ly-1 B repertoire,
but pose the question as to why such selection preferentially
occurs in the Ly-1 B population. This question remains the
focus of future investigation.
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